Navigation Links
TorreyPines Announces the Adjournment of Its Special Meeting of Stockholders
Date:7/9/2009

LA JOLLA, Calif., July 9 /PRNewswire/ -- TorreyPines Therapeutics, Inc. ("TPTX") announced today that its Special Meeting of Stockholders, which was convened on July 9, 2009, was adjourned to July 16, 2009 at 9:00 a.m., local time, at TPTX's offices located at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA 92130. As discussed in the Proxy Statement distributed to stockholders on or about June 19, 2009, the stockholders of TPTX were scheduled to vote upon a proposal to approve the liquidation and dissolution of TPTX pursuant to a Plan of Liquidation and Dissolution. Sixty-two percent (62%) of TPTX's stockholders failed to return their proxy cards or otherwise indicate their votes with respect to this proposal prior to the start of the Special Meeting. In order to pass, this proposal must be approved by holders of at least a majority of TPTX's outstanding voting shares, and as a result, abstentions and non-votes have the same effect as votes against the proposal.

Ninety-seven percent (97%) of the stockholders present at the meeting in person or voting by proxy approved the proposal to adjourn and reconvene the Special Meeting to permit further solicitation of proxies since there were not sufficient votes at the Special Meeting to approve the Plan of Liquidation and Dissolution. Stockholders who have not voted on the proposals described in the Proxy Statement are encouraged to do so promptly. For stockholders that have already voted on the proposals, no additional action is necessary if you do not wish to change your vote. Proxies may be submitted or revoked at any time prior to the reconvening of the adjourned meeting on July 16, 2009. For assistance in voting your shares, please contact TPTX's investor relations department at 858-623-5665 x158.

Stockholders of TPTX are urged to read the Proxy Statement, which contains important information about the Special Meeting and the proposals to be voted upon and it should be read carefully before any decision is made with respect to the matters to be voted upon.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665 X125
    pschneider@TPTXinc.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
6. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
7. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
8. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows Regional ... – Somers Point, NJ. The new clients range in bed size from 57 to ... solution and its interoperability. , Houston Methodist is a leading academic medical center comprised ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced by Prox Formulas ... and dedicated athletes, continues to transform the nutritional supplement industry by providing a safe, ... protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute officially starts ... 8-night special intensive summer training camp starts on June 17th on Shaolin Institute ... and children a fun and unique experience with an opportunity to learn KungFu ...
(Date:5/29/2016)... ... ... "With 30 unique self-animating web themed intros and complete control over customization, ... Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume 3 ... Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a sleek ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology: